Shares in Belgian biotech company Argenx plunged by 15% following a setback in the clinical development of its drug, Vyvgart. De Tijd reports this news, based on a company announcement. Argenx has decided to discontinue the late-stage study for Vyvgart as a candidate treatment for the chronic autoimmune Sjögren's disease, leading to an immediate sharp market reaction.
Clinical trials for Sjögren's disease discontinued
Argenx has definitively halted the ongoing Phase 3 study for Vyvgart in the treatment of Sjögren's disease. This decision follows an analysis of the data collected so far, which indicated that the drug's efficacy did not meet expectations for this specific indication. The premature termination of a clinical study at an advanced stage is a rare but necessary step when results are not promising, and further investment is no longer justified.
Argenx stock plummets on Euronext Brussels
The discontinuation of the study had an immediate and tangible impact on Argenx's market valuation. At the opening of trading, the company's shares, listed on Euronext Brussels, dropped by a significant 15%. This underscores the inherent volatility and risks associated with investments in the biotech sector, where the success or failure of a single drug program can drastically affect a company's market value. For Argenx, this represents a challenge to regain investor confidence after this unexpected setback.
Argenx's broader pipeline and existing approvals
Despite the disappointing results for Sjögren's disease, Argenx remains a prominent player in developing innovative treatments for autoimmune conditions. Vyvgart is already approved for other indications, including generalized myasthenia gravis, and forms a critical part of the Ghent-based biotech firm's product portfolio. The company boasts a broad pipeline with multiple programs in various clinical stages, targeting diverse autoimmune disorders. The focus will now shift to advancing these other promising studies and maximizing value from Vyvgart's existing approvals.
